Evaluation of the safety and efficacy of a triple combination cream (hydroquinone, tretinoin, and fluocinolone) for treatment of melasma in Middle Eastern skin

References

• Cestari T, Arellano I, Hexsel D, Ortonne J, Academy LAPD. Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(7):760–772. doi:10.1111/j.1468-3083.2009.03251.x19646135
   PubMed Web of Science ®Google Scholar
• Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010;7(7).CD003583
   Google Scholar
• Shankar K, Godse K, Aurangabadkar S, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb). 2014;4(2):165–186. doi:10.1007/s13555-014-0064-z25269451
   PubMedGoogle Scholar
• Kwon SH, Hwang YJ, Lee SK, Park KC. Heterogeneous pathology of melasma and its clinical implications. Int J Mol Sci. 2016;17(6). doi:10.3390/ijms17060824
   Web of Science ®Google Scholar
• Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67–73.12889718
   PubMed Web of Science ®Google Scholar
• Jimbow K, Obata H, Pathak MA, Fitzpatrick TB. Mechanism of depigmentation by hydroquinone. J Invest Dermatol. 1974;62(4). doi:10.1111/1523-1747.ep12701679
   Web of Science ®Google Scholar
• Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048–1065. doi:10.1016/j.jaad.2006.02.00917097400
   PubMed Web of Science ®Google Scholar
• Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients: a vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727–733.8002642
   PubMedGoogle Scholar
• Rendon M. Utilizing combination therapy to optimize melasma outcomes. J Drugs Dermatol. 2004;3(5 Suppl):S27–S34.15552597
   PubMedGoogle Scholar
• Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis. 2005;75(1):57–62.15732437
   PubMed Web of Science ®Google Scholar
• Chan R, Park K, Lee M, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0·01%, hydroquinone 4%, tretinoin 0· 05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159(3):697–703. doi:10.1111/j.1365-2133.2008.08717.x18616780
   PubMed Web of Science ®Google Scholar
• Torok HM. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream. Am J Clin Dermatol. 2006;7(4):223–230.16901182
   PubMed Web of Science ®Google Scholar
• Pandya AG, Hynan LS, Bhore R, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(1):78–83. e2. doi:10.1016/j.jaad.2009.10.05120398960
   PubMed Web of Science ®Google Scholar
• Prignano F, Ortonne J-P, Buggiani G, Lotti T. Therapeutical approaches in melasma. Dermatol Clin. 2007;25(3):337–342. doi:10.1016/j.det.2007.04.00617662899
   PubMed Web of Science ®Google Scholar
• Malakooti S, Nasrollahi SA, Kashani MN, et al. Formulation of triple cream for treatment of melasma. Jundishapur J Nat Pharm Prod. 2019;14(2).
   Web of Science ®Google Scholar
• Balkrishnan R, Kelly A, McMichael A, Torok H. Improved quality of life with effective treatment of facial melasma: the pigment trial. J Drugs Dermatol. 2004;3(4):377–381.15303781
   PubMedGoogle Scholar
• Cestari TF, Hexsel D, Viegas M, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL‐BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006;156:13–20. doi:10.1111/j.1365-2133.2006.07591.x17176300
   PubMed Web of Science ®Google Scholar
• Pasricha J, Khaitan BK, Dash S. Pigmentary disorders in India. Dermatol Clin. 2007;25(3):343–352. doi:10.1016/j.det.2007.05.00417662900
   PubMed Web of Science ®Google Scholar
• Halder R, Grimes P, McLaurin C, Kress M, Kenney JJ. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(4):388–390.6226496
   PubMed Web of Science ®Google Scholar
• Ferreira Cestari T, Hassun K, Sittart A. de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007;6(1):36–39. doi:10.1111/j.1473-2165.2007.00288.x17348994
   PubMedGoogle Scholar
• Sivayathorn A. Melasma in orientals. Clin Drug Investig. 1995;10(2):34–40. doi:10.2165/00044011-199500102-00006
   Google Scholar
• Grimes P, Kelly AP, Torok H, Willis I. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis. 2006;77(3):177–184.16610738
   PubMed Web of Science ®Google Scholar
• Arellano I, Cestari T, Ocampo‐Candiani J, et al. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long‐standing clinical severity. J Eur Acad Dermatol Venereol. 2012;26(5):611–618.21623930
   PubMed Web of Science ®Google Scholar
• Wolverton SE. Comprehensive Dermatologic Drug Therapy. Oxford (UK). Elsevier Health Sciences; 2012.
   Google Scholar
• Khunger N, Sarkar R, Jain R. Tretinoin peels versus glycolic acid peels in the treatment of melasma in dark‐skinned patients. Dermatol Surg. 2004;30(5):756–760. doi:10.1111/j.1524-4725.2004.30212.x15099320
   PubMed Web of Science ®Google Scholar
• Khanna N, Rasool S. Facial melanoses: indian perspective. Indian J Dermatol Venereol Leprol. 2011;77(5):552. doi:10.4103/0378-6323.8404621860153
   PubMed Web of Science ®Google Scholar
• Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006;54(5):S272–S81. doi:10.1016/j.jaad.2005.12.03916631968
   PubMed Web of Science ®Google Scholar
• Kong R, Cui Y, Fisher GJ, et al. A comparative study of the effects of retinol and retinoic acid on histological, molecular, and clinical properties of human skin. J Cosmet Dermatol. 2016;15(1):49–57. doi:10.1111/jocd.1219326578346
   PubMed Web of Science ®Google Scholar
• Kang HY, Valerio L, Bahadoran P, Ortonne J-P. The role of topical retinoids in the treatment of pigmentary disorders. Am J Clin Dermatol. 2009;10(4):251–260.19489658
   PubMed Web of Science ®Google Scholar
• Kanwar A, Dhar S, Kaur S. Treatment of melasma with potent topical corticosteroids. Dermatology. 1994;188(2):170. doi:10.1159/0002471298136550
   PubMed Web of Science ®Google Scholar
• Bhawan J, Grimes P, Pandya AG, et al. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. Am J Dermatopathol. 2009;31(8):794–798. doi:10.1097/DAD.0b013e3181a9070d19755910
   PubMed Web of Science ®Google Scholar
• Guevara IL, Werlinger KD, Pandya AG. Tolerability and efficacy of a novel formulation in the treatment of melasma. J Drugs Dermatol. 2010;9(3):215–218.20232581
   PubMed Web of Science ®Google Scholar
• Seth V, Pandya A. Melasma: a comprehensive update part II. J Am Acad Dermatol. 2011;65:699–711. doi:10.1016/j.jaad.2011.06.00121920242
   PubMed Web of Science ®Google Scholar